Edwards Lifesciences Corporation (NYSE:EW) went up by 0.26% from its latest closing price compared to the recent 1-year high of $131.73. The company’s stock price has collected -1.34% of loss in the last five trading sessions. Press Release reported on 01/05/22 that EDWARDS LIFESCIENCES TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Is It Worth Investing in Edwards Lifesciences Corporation (NYSE :EW) Right Now?
Edwards Lifesciences Corporation (NYSE:EW) scored a price-to-earnings ratio above its average ratio, recording 52.38 x from its present earnings ratio. Plus, the 36-month beta value for EW is at 1.10. Opinions of the stock are interesting as 16 analysts out of 26 who provided ratings for Edwards Lifesciences Corporation declared the stock was a “buy,” while 1 rated the stock as “overweight,” 9 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $132.55, which is $7.26 above the current price. EW currently public float of 619.72M and currently shorts hold a 0.98% ratio of that float. Today, the average trading volume of EW was 2.34M shares.
EW’s Market Performance
EW stocks went down by -1.34% for the week, with a monthly jump of 1.26% and a quarterly performance of 12.06%, while its annual performance rate touched 36.97%. The volatility ratio for the week stands at 2.49% while the volatility levels for the past 30 days are set at 2.34% for Edwards Lifesciences Corporation. The simple moving average for the period of the last 20 days is -2.11% for EW stocks with a simple moving average of 12.46% for the last 200 days.
Analysts’ Opinion of EW
Many brokerage firms have already submitted their reports for EW stocks, with JP Morgan repeating the rating for EW by listing it as a “Overweight.” The predicted price for EW in the upcoming period, according to JP Morgan is $140 based on the research report published on December 17th of the previous year 2021.
Citigroup, on the other hand, stated in their research note that they expect to see EW reach a price target of $142, previously predicting the price at $120. The rating they have provided for EW stocks is “Buy” according to the report published on December 15th, 2021.
RBC Capital Mkts gave a rating of “Outperform” to EW, setting the target price at $142 in the report published on December 10th of the previous year.
EW Trading at 2.47% from the 50-Day Moving Average
After a stumble in the market that brought EW to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.19% of loss for the given period.
Volatility was left at 2.34%, however, over the last 30 days, the volatility rate increased by 2.49%, as shares surge +4.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.80% upper at present.
During the last 5 trading sessions, EW fell by -1.34%, which changed the moving average for the period of 200-days by +47.57% in comparison to the 20-day moving average, which settled at $125.16. In addition, Edwards Lifesciences Corporation saw -5.63% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at EW starting from WANG HUIMIN, who sale 6,350 shares at the price of $122.16 back on Jan 07. After this action, WANG HUIMIN now owns 98,027 shares of Edwards Lifesciences Corporation, valued at $775,716 using the latest closing price.
MUSSALLEM MICHAEL A, the Chairman & CEO of Edwards Lifesciences Corporation, sale 32,550 shares at $123.88 during a trade that took place back on Jan 06, which means that MUSSALLEM MICHAEL A is holding 188,002 shares at $4,032,200 based on the most recent closing price.
Stock Fundamentals for EW
Current profitability levels for the company are sitting at:
- +29.55 for the present operating margin
- +74.94 for the gross margin
The net margin for Edwards Lifesciences Corporation stands at +18.77. The total capital return value is set at 25.67, while invested capital returns managed to touch 16.40. Equity return is now at value 29.70, with 19.50 for asset returns.
Based on Edwards Lifesciences Corporation (EW), the company’s capital structure generated 15.19 points at debt to equity in total, while total debt to capital is 13.19. Total debt to assets is 9.60, with long-term debt to equity ratio resting at 14.60. Finally, the long-term debt to capital ratio is 12.67.
When we switch over and look at the enterprise to sales, we see a ratio of 14.80, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 7.30 and the total asset turnover is 0.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.46.